GPS
The Gap, Inc.
stockNYSE

Here come the experts. While this bs dump blames Musk for aiding Russia, Ukraine blames Musk for not aiding Ukraine as much as before, and Russia blames Musk for aiding Ukraine too much. The fact is, SpaceX is too big to be out of this monkey business, and everyone wants their products and services - namely Starlink. Ukraine built their entire war effort on Starlink, initially donated by Musk (along with subscriptions) to help refugees in Ukraine. Instead of refugees, terminals went straight into battle, then onto long-range combat drones, which destroyed Russia's Black sea fleet. All of it. That was how it worked until recently. With a little bit of a problem being all that was a violation of terms of service. So Musk or whoever tuned the settings so that high-velocity terminals stopped working. Ukraine hacked the hardware, replaced the GPS part with some hackery that worked around it, but eventually it stopped working. Accusations started immediately, as if Musk is Ukrainian and SpaceX is a Ukrainian company. Russia used Starlink a little, as it works only near Ukraine. But now they have their own version of Starlink, and don't need the original. SpaceX and Musk tolerate(d) all this only because US government wished so, but apparently now they want out of the whole bloody mess. Musk certainly took note of Jensen's fate, and certainly is making arrangements so that any attempt is made impossible or self-defeating. At war, anything goes, and this is clearly war, with NVDA being the first hit.

$20/share or $20 billion buyout? That would be a ridiculously low share price on fda approval, when valuation will likely be higher than $4 billion on GPS alone. There are other drugs in the pipeline so $20 is low for a jump in SP even if they just sold the rights to GPS rather than a BO

$SLS has reported it will in fact release the top-line results of its Regal Phase 3 clinical trial of GPS by the end of this month. The quote: “Phase 3 REGAL Trial of GPS: Ongoing Phase 3 trial in AML patients who have achieved complete remission following second-line salvage therapy. In October 2026, the Company announced the required pre-specified 80th event occurred, triggering the customary database lock, blinded data review procedures before statistical analysis, unblinding, and disclosure of topline results, which the Company expects to report this month.” https://www.globenewswire.com/news-release/2026/11/12/3402212/0/en/sellas-life-sciences-reports-third-quarter-2026-financial-results-and-provides-corporate-update.html

* KOD @ $85 (above water): 31.25% of my initial biotech holdings. It'll be interesting to see the readout of KSI-101 in December. * GMAB @ $57 (under water) 15.625% of my initial biotech holdings. Jumped in too high, but I think downside is limited to ~$45. Will probably average down if it goes into the high $40s and sell calls against my position after that. * INO @ $1.75 (under water) 21.875% of my initial biotech holdings. Feel like it should be valued in the high $2s, but I'm also worried that VOCERYQ will have a shitty launch. * GENB @ $14 (under) 31.25% of my initial holdings. Regretting this one because I generally avoid "platform" companies (i.e. companies that say "we've got a special 'method' for making drugs.") Made decent $ on LQDA, but I'm out. I don't understand the SLS worship around here (I think the GPS is DOA), but it's certainly entertaining watching from the sidelines. I'd bet against SLS, but the puts are expensive and I don't have the mental fortitude to take large short positions.

It’s a slow process but you’ll be able to file an insurance claim through your vendor if it was shipped with insurance. File a police report unless you somehow know where it was delivered and the resident gives up the package. FedEx has GPS coordinates for where it was delivered but probably won’t give them to you. When a package of mine was misdelivered, the vendor had me file a police report. Until that was done fedex stonewalled and just kept saying it was delivered correctly even though the photo was clearly not my property. Once the police report was in FedEx then admitted it was not given to me and the insurance claim was processed. It took like 3 months but the vendor was able to send me a replacement shipment.

did one of these in the summer and a few people asked for the next round so here it is. Everything is under $10 and has an event the company itself has dated or guided inside roughly the next 3 months. If the company didn't say it, it's not on here. Quick thing first. All three PDUFAs this month land on a weekend. Nov 22 is a Sunday, Nov 28 is a Saturday, Dec 12 is a Saturday. FDA often acts on the business day before, so don't plan around Monday morning. The FDA dates SVRA (Savara), Nov 22. Molgramostim (Molbreevi) for autoimmune PAP. This was supposed to be Aug 22 and got pushed 3 months because FDA called their answers to info requests a major amendment. No safety or efficacy issue was cited, and that's the part I keep coming back to. Short interest is 31% of float which is a lot for a name going into a PDUFA. The catch is cash. Roughly $130M at end of September, call it 9 months at their burn. So approval or not I'd expect a raise at some point. PYPD (PolyPid), Nov 28. D-PLEX100 for preventing surgical site infections. Priority review. Their Phase 3 (SHIELD II) showed about a 60% relative risk reduction. Azurity has US rights and is talking early 2027 launch. Stock is already up 38% in 3 months so some of this is in the price. VNDA (Vanda), Dec 12. Imsidolimab for GPP (generalized pustular psoriasis). GEMINI-1 had 53% clear or almost clear at week 4 vs 13% on placebo. Spesolimab is the drug it gets compared to. Vanda is down about half this year which honestly makes the setup more interesting than the drug. Readouts guided for Q4 / year end SLS (Sellas). Hit the 80th event in the REGAL trial (GPS in AML) on Oct 28 and said topline comes this quarter. Stock dropped 18% that day which tells you how split people are. Overall survival endpoint, as binary as it gets. SI 29%. ANNX (Annexon). ARCHER II in geographic atrophy, 659 patients, Q4. The primary is stopping 15+ letter vision loss, which is a different bar than the approved GA drugs got through on. If it hits that's a real talking point. RGNX (Regenxbio). ATMOSPHERE and ASCENT with AbbVie, subretinal gene therapy in wet AMD, 1,200+ patients across both. Q4. Big partner, big trials, smallish stock. IMUX (Immunic). ENSURE-1 and ENSURE-2 in relapsing MS, 2,200 patients combined, guided by end of 2026. They already passed an interim futility look. Stock is down about half in 3 months so expectations aren't exactly high. Q3 report should be out any day, watch whether they repeat the timing. RZLT (Rezolute). upLIFT in tumor HI, small single arm study. 6 of the first 8 hit the primary at interim. But their congenital HI Phase 3 missed last December and people remember. H2 2026 guided. ACRS (Aclaris). Bosakitug (anti-TSLP) Phase 2 in atopic dermatitis, 109 patients, placebo controlled, Q4. Edge of the window, early 2027 AVIR (Atea). C-FORWARD in hep C. The North America trial already hit non-inferiority vs Epclusa in July, this is the second one, pushed from year end to early Q1 2027. Second trial after the first one already won is usually less drama. OLMA (Olema). OPERA-01, palazestrant in ER+/HER2- breast cancer, moved to Q1 2027 with enrollment done. 24% SI and down 68% this year. And CMPS isn't a readout, it's the rolling NDA for COMP360 in treatment resistant depression wrapping up this quarter. Slow burn one. What I'm avoiding Anything with a catalyst and no cash. DWTX has a Phase 2b readout guided for this quarter but had about $5M at end of September. That's 3 months. LGVN, SKYE and TVRD are all around 1 to 2 months of runway on their last filing and MBRX is basically zero. Good data and an offering the same morning is the most common way people lose money in this sector. Stuff that looked great on my list and wasn't EYPT showed up as a Q4 Phase 3 readout in wet AMD. Both trials already read out and missed, stock is down 97%. XFOR showed as Q4 too but the Phase 3 is now 2028. MPLT's schizophrenia Phase 2 was on my list and it already came out positive back in July. ZNTL was guided year end and quietly slid to first half 2027. So check the latest 10-Q or press release before you trust any calendar, including this one.

A couple of things. 1. Headline inflation (cpi-u) leaves out important things from the basket that everyday people *actually feel* like home purchase prices, interest costs on mortgages, car loans, and credit cards. Myself and many people I know view headline inflation like GPS in 2001. IYKYK. 2. People do talk about it, just probably not in your average social circle. Headline vs Real is a popular topic in my line of work, especially related to inflation and labor markets. Consider headline unemployment (U-3) which supports the narrative of a “low hire low fire” environment, vs Real (U6) which has been \~8% for the past 5 years. 3. Policy makers use PCE for their “2% target” which has a different methodology than headline inflation, maybe better maybe worse depending on the basis of discussion. 4. Perhaps most concerning to me, earlier this year the Fed **changed the math for calculating PCE** and applied it retroactively to 2021, materially *reducing* the inflation prints for the past 5 years. Remains to be seen the full implications but this is more related to your point about the gov skewing numbers. 5. In isolation, the numbers are just a biased data point. In tandem, they point to underlying trends which algos eat up. In abstract, they don’t mean shit to the average “consumer” or real person/family that’s getting bent over no matter what “basket” they spend their money on.

Starting to look into an interesting company, anyone here follow them? Company is Badger Infrastructure Solutions Ltd (TSX:BDGI/BDGIF). What they do: >Badger Infrastructure Solutions Ltd. provides non-destructive excavating and related services to utilities, industrial, construction, transportation, and other industries in Canada and the United States. >It offers Badger Hydrovac for use in safe excavations around critical infrastructure and in congested underground conditions. >The company also provides hydrovac services, such as anode installations, daylighting, debris removal, pipelines, potholing, power distribution, service pits, shoring installations, tank cleanouts, trenching, and utility pole holes; and electromagnetic locating, GPS data collection, infrastructure mapping, depth of cover surveys, 4-way sweeps and passive scans, daylight reports, CAD drawings and GIS exports, and watch and protect inspections services. >In addition, it offers sewer services, including air testing, CCTV inspections, flushing and cleaning, laser profiling, mainline to lateral inspections, Mandrel testing, reaming and concrete removal, sewer and main line locating, and smoke testing; and disaster response services related to large scale natural disasters comprising hurricanes, floods, and large-scale fires. Valuation: [https://stockanalysis.com/quote/tsx/BDGI/statistics/](https://stockanalysis.com/quote/tsx/BDGI/statistics/) Latest Investor Presentation [https://s201.q4cdn.com/142671057/files/content\_files/Badger-Baird-Conference-Presentation-November-2026-VFINAL1.pdf](https://s201.q4cdn.com/142671057/files/content_files/Badger-Baird-Conference-Presentation-November-2026-VFINAL1.pdf)

I had seen a few discussions around it on Investorshub and noticed a significant number of people posting their calls and being bullish. A shareholder posted research notes about GPS and their strategy discussing pipeline focus, clinical candidates, and the upcoming REGAL Phase 3 results. It met a lot of the criteria I look for in an early biotech.